Carlos Bermudez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carlos Bermudez has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Salto
Universidad Nacional de La Pampa
4 shared publications - Gabriela Minetti
Universidad Nacional de La Pampa
3 shared publications - Hugo Alfonso
Universidad Nacional de La Pampa
3 shared publications - Aleksandr A. Isaev
JSC BIOCAD, Saint Petersburg, Russia
1 shared publication Ana Madera Rojas
GREICAH (Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas), Bogotá D. C., Colombia
1 shared publication- Angela M. Peña
Hematology and Hematopoietic Stem Cell Transplantation Unit, Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia
1 shared publication
Latest Publications
- Open Access
- 16 January 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 369-381
Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60–98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.
- 16 January 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 369-381
Open AccessCharacteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60–98), 55% were men, 61% had an ECOG < 2, and 75.5% had de novo AML. FLT3-ITD or NPM1 mutations were performed in 23.4% and 15.6% patients, and detected in 14.3% and 16.7% of cases, respectively. Treatment included intensive chemotherapy (IC) (36.8%), Low-Intensity Regimen Based on Low-Dose Cytarabine (LDAC-based) (12.6%), hypomethylating agents (HMAs, with/without venetoclax) (35.3%), and supportive care (15.2%). The overall survival (OS) rate was 35.2% at 1 year and 5.6% at 5 years (13.7% for IC, 9.4% for LDAC-based, and 0% for other treatments); with median OS of 8.2 months (10.6 months after IC, 8.8 months after non-IC, 8.9 months after azacitidine/decitabine, 8.2 months after azacitidine-venetoclax, and 1.9 months with supportive care). Only 1.5% of patients underwent a transplant in the first line. The Leukemia-free survival (LFS) rate was 45.8% at 1-year and 13.7% at 5-years (22.4% for IC, 9.4% and 0% for other treatments); with median LFS of 9.5 months (17.3 months after IC, 7.4 months after LDAC-based, and 10.8 months after HMA). This study provides new insights into the management of patients in Colombia, highlighting the need for a highly individualized approach in treating AML in elderly patients.
- 20 May 2022
- Published by Springer Nature
- p. 3-17
Internal Behavior Analysis of SA Using Adaptive Strategies to Set the Markov Chain Length
- 20 May 2022
- Published by Springer Nature
- p. 3-17
Internal Behavior Analysis of SA Using Adaptive Strategies to Set the Markov Chain Length
- 15 September 2021
- Published by Springer Nature
- p. 625-636
A Parallel Optimization Solver for the Multi-period WDND Problem
- 15 September 2021
- Published by Springer Nature
- p. 625-636
A Parallel Optimization Solver for the Multi-period WDND Problem
- 5 May 2021
- Published by Springer Nature
- p. 19-34
Hybrid Simulated Annealing to Optimize the Water Distribution Network Design: A Real Case
- 5 May 2021
- Published by Springer Nature
- p. 19-34
Hybrid Simulated Annealing to Optimize the Water Distribution Network Design: A Real Case
- Open Access
- 26 May 2020
- Published by Universidad Nacional de La Plata in Journal of Computer Science and Technology
- Vol. 20 (1) , e04
Parallelism and Hybridization in Differential Evolution to solve the Flexible Job Shop Scheduling Problem
Flexible Job Shop Scheduling Problem (FJSP) is one of the most challenging combinatorial optimization problems, with practical applicability in a real production environment. In this work, we propose a simple Differential Evolution (DE) algorithm to tackle this problem. To represent an FJSSP solution, a real value representation is adopted, which requires a very simple conversion mechanism to obtain a feasible schedule. Consequently, the DE algorithm still works on the continuous domain to explore the problem search space of the discrete FJSSP. Moreover, to enhance the local searchability and to balance the exploration and exploitation capabilities, a simple local search algorithm is embedded in the DE framework. Also, the parallelism of the DE operations is included to improve the efficiency of the whole algorithm. Experiment results confirm the significant improvement achieved by integrating the propositions introduced in this study. Additionally, test results show that our algorithm is competitive when compared with most existing approaches for the FJSSP.
- 26 May 2020
- Published by Universidad Nacional de La Plata in Journal of Computer Science and Technology
- Vol. 20 (1) , e04
Open AccessParallelism and Hybridization in Differential Evolution to solve the Flexible Job Shop Scheduling Problem
Flexible Job Shop Scheduling Problem (FJSP) is one of the most challenging combinatorial optimization problems, with practical applicability in a real production environment. In this work, we propose a simple Differential Evolution (DE) algorithm to tackle this problem. To represent an FJSSP solution, a real value representation is adopted, which requires a very simple conversion mechanism to obtain a feasible schedule. Consequently, the DE algorithm still works on the continuous domain to explore the problem search space of the discrete FJSSP. Moreover, to enhance the local searchability and to balance the exploration and exploitation capabilities, a simple local search algorithm is embedded in the DE framework. Also, the parallelism of the DE operations is included to improve the efficiency of the whole algorithm. Experiment results confirm the significant improvement achieved by integrating the propositions introduced in this study. Additionally, test results show that our algorithm is competitive when compared with most existing approaches for the FJSSP.
- 14 November 2019
- Published by Wiley in Hematological Oncology
- Vol. 38 (1) , 67-73
Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial
BCD‐020 is a proposed rituximab biosimilar, which has shown high similarity to rituximab in quality and nonclinical studies in vitro and in vivo.International multicenter clinical trial was conducted to compare efficacy and safety of BCD‐020 and reference rituximab in adult (older than 18 years) patients with indolent lymphomas (follicular lymphoma grade 1‐2, splenic marginal zone lymphoma, and nodal marginal zone lymphoma). Pharmacokinetics, pharmacodynamics, and immunogenicity were also studied.Patients with no previous biologic treatment for lymphoma were randomly assigned 1:1 to receive BCD‐020 or comparator 375 mg/m2 for 4 weeks.Primary study outcome was day 50 overall response rate defined as complete or partial remission. Equivalence range was −20% to 20% for 95% CI for overall response rates difference. Secondary outcomes included adverse events, pharmacokinetics, pharmacodynamics, and immunogenicity.One hundred seventy‐four patients were enrolled, 89 in BCD‐020 arm and 85 in comparator arm. The overall response rate was 44.71% in BCD‐020 arm and 41.89% in comparator arm. Limits of 95% confidence interval (CI) for difference of overall response rates between arms were (−12.62%‐18.24%) showing equivalent efficacy. Sixty‐one (68.54%) and 59 (69.41%) patients had at least one adverse event in BCD‐020 arm or comparator arm, respectively. No unexpected adverse reactions were reported.Antidrug antibodies with no neutralizing activity were detected in two patients in comparator arm on day 14 further declining below detection threshold.Rituximab concentrations had equivalent pattern after intravenous administration of both drugs. Both drugs caused depletion of B‐cells without significant influence on other blood cell lineages.In this study, we showed equivalent efficacy of BCD‐020 and reference rituximab when used in patients with CD20‐positive indolent lymphomas. We also confirmed pharmacokinetic equivalence of BCD‐020 and reference rituximab. Safety profile, pharmacodynamics, and immunogenicity of BCD‐020 were also comparable with those of reference rituximab.
- 14 November 2019
- Published by Wiley in Hematological Oncology
- Vol. 38 (1) , 67-73
Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial
BCD‐020 is a proposed rituximab biosimilar, which has shown high similarity to rituximab in quality and nonclinical studies in vitro and in vivo.International multicenter clinical trial was conducted to compare efficacy and safety of BCD‐020 and reference rituximab in adult (older than 18 years) patients with indolent lymphomas (follicular lymphoma grade 1‐2, splenic marginal zone lymphoma, and nodal marginal zone lymphoma). Pharmacokinetics, pharmacodynamics, and immunogenicity were also studied.Patients with no previous biologic treatment for lymphoma were randomly assigned 1:1 to receive BCD‐020 or comparator 375 mg/m2 for 4 weeks.Primary study outcome was day 50 overall response rate defined as complete or partial remission. Equivalence range was −20% to 20% for 95% CI for overall response rates difference. Secondary outcomes included adverse events, pharmacokinetics, pharmacodynamics, and immunogenicity.One hundred seventy‐four patients were enrolled, 89 in BCD‐020 arm and 85 in comparator arm. The overall response rate was 44.71% in BCD‐020 arm and 41.89% in comparator arm. Limits of 95% confidence interval (CI) for difference of overall response rates between arms were (−12.62%‐18.24%) showing equivalent efficacy. Sixty‐one (68.54%) and 59 (69.41%) patients had at least one adverse event in BCD‐020 arm or comparator arm, respectively. No unexpected adverse reactions were reported.Antidrug antibodies with no neutralizing activity were detected in two patients in comparator arm on day 14 further declining below detection threshold.Rituximab concentrations had equivalent pattern after intravenous administration of both drugs. Both drugs caused depletion of B‐cells without significant influence on other blood cell lineages.In this study, we showed equivalent efficacy of BCD‐020 and reference rituximab when used in patients with CD20‐positive indolent lymphomas. We also confirmed pharmacokinetic equivalence of BCD‐020 and reference rituximab. Safety profile, pharmacodynamics, and immunogenicity of BCD‐020 were also comparable with those of reference rituximab.